Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
41.38
+0.48 (1.17%)
Jan 21, 2025, 4:00 PM EST - Market closed
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
610.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | 137.88K | 2.88K | 2.13% |
| Dec 31, 2013 | 135.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
TECX News
- 16 days ago - Tectonic Therapeutic: Protein Engineering Platform For GPCRs - Seeking Alpha
- 7 weeks ago - Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 - GlobeNewsWire
- 2 months ago - Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 - GlobeNewsWire
- 3 months ago - Tectonic Therapeutic: Interesting CV Disease Drug Developer - Seeking Alpha
- 4 months ago - Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewsWire
- 5 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire